Cargando…

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital

INTRODUCTION: Vernal conjunctivitis comprises 0.5% of allergic eye diseases. The study is intended to collate the effectiveness of drugs by observing the reduction in signs and symptoms. OBJECTIVES: The objective of the study is to evaluate the effectiveness and safety of olopatadine 0.1% ophthalmic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sruthi, Vadlakonda, Reddy, Resu Neha, Sowmini, K., Grace, Nagur Sharone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092179/ https://www.ncbi.nlm.nih.gov/pubmed/33666188 http://dx.doi.org/10.4103/ijp.IJP_174_20

Ejemplares similares

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis
por: Xu, Xuegu, et al.
Publicado: (2019)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index
por: Mohan, S, et al.
Publicado: (2023)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Vernal keratoconjunctivitis
por: Addis, Hampton, et al.
Publicado: (2018)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

UV spectrophotometric methods for simultaneous determination of ketorolac tromethamine and olopatadine hydrochloride: Application of multiple standard addition for assay of ophthalmic solution
por: Hammad, Sherin F., et al.
Publicado: (2023)

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials
por: Leonardi, Andrea, et al.
Publicado: (2022)

Allergy to ophthalmic solutions
por: Lapeere, Hilde, et al.
Publicado: (2014)

Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex
por: Kato, C. O. Sayaka, et al.
Publicado: (2018)

Management of Vernal Keratoconjunctivitis
por: Leonardi, Andrea
Publicado: (2013)

Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis
por: Wakamatsu, Tais Hitomi, et al.
Publicado: (2011)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis
por: Saha, Bhawesh Chandra, et al.
Publicado: (2023)

Vitiligo in association with vernal keratoconjunctivitis
por: Kumar, Sunil, et al.
Publicado: (2016)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children
por: Bourcier, Tristan, et al.
Publicado: (2022)

Clinical Outcomes of Topical 0.1% Ciclosporin Cationic Emulsion Used on Label in Children with Vernal Keratoconjunctivitis
por: Giannaccare, Giuseppe, et al.
Publicado: (2023)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis
por: Al-Amri, Abdulrahman M., et al.
Publicado: (2016)

Role of ocular cytology in vernal keratoconjunctivitis
por: Bruschi, Gaia, et al.
Publicado: (2019)

Vernal Keratoconjunctivitis: A Systematic Review
por: Bruschi, Gaia, et al.
Publicado: (2023)

Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series
por: Sung, Jonathan, et al.
Publicado: (2022)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Stability and Safety Traits of Novel Cyclosporine A and Tacrolimus Ophthalmic Galenic Formulations Involved in Vernal Keratoconjunctivitis Treatment by a High-Resolution Mass Spectrometry Approach
por: Ghiglioni, Daniele Giovanni, et al.
Publicado: (2020)

Ophthalmic regional blocks: management, challenges, and solutions
por: Palte, Howard D
Publicado: (2015)

Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: Recommendations From the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group
por: Mehta, Jodhbir S., et al.
Publicado: (2022)

Conjunctival Injection Reduction in Patients with Atopic Keratoconjunctivitis Due to Synergic Effect of Bovine Enteric-Coated Lactoferrin in 0.1% Tacrolimus Ophthalmic Suspension
por: Fujishima, Hiroshi, et al.
Publicado: (2020)

Influence of container structures and content solutions on dispensing time of ophthalmic solutions
por: Yoshikawa, Keiji, et al.
Publicado: (2010)

Management of vernal keratoconjunctivitis in children in Saudi Arabia
por: AlHarkan, Dora Hamad
Publicado: (2020)

Corneal and lens densitometry in patients with vernal keratoconjunctivitis
por: Yılmaz, Yusuf Cem, et al.
Publicado: (2021)

Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives
por: Chigbu, DeGaulle I., et al.
Publicado: (2021)

Understanding Vernal Keratoconjunctivitis: Beyond Allergic Mechanisms
por: Sacchetti, Marta, et al.
Publicado: (2021)

Vernal keratoconjunctivitis: state of art and update on treatment
por: Brindisi”, Giulia, et al.
Publicado: (2021)

Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study
por: Chen, Minjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q3juoioc1cf0e1rl64p0o85v17